1/6 馃Л #ESMO2026 could reshape oncology competition beyond new targets.
Phase III data will test clinical differentiation in ADCs, NSCLC sequencing and treatment intensification.
#LucidQuest's preview https://bit.ly/3UhRLVh and the strategic signals we're watching. 馃У @myESMO
134 views 路 0 likes 路 1 repost 路 5 replies
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Dr Timos Papagatsias@_timos_
6/6 馃憖 Post-ESMO Watchpoints Will Phase III data clarify ADC differentiation, treatment intensification and NSCLC sequencing? Can AI-enabled tools demonstrate patient benefit? #Oncology #CompetitiveIntelligence #AIinHealthcare
- Dr Timos Papagatsias@_timos_
5/6 馃 AI/ML in Oncology ALLIANCE will test LLM-assisted chemotherapy toxicity management. HOPE will assess personalized digital supportive care. AI-driven pathology and decision-support tools face a critical test: measurable clinical utility.
- Dr Timos Papagatsias@_timos_
4/6 馃Л Industry Signals 馃敼 Pfizer: Long-term lorlatinib evidence. 馃敼 Novartis: Risk-based CDK4/6 inhibition. 馃敼 Gilead/Kite: ADC positioning in metastatic TNBC. 馃敼 DeLLphi-305: DLL3-directed maintenance therapy in SCLC.
- Dr Timos Papagatsias@_timos_
3/6 馃幆 NSCLC Sequencing Krascendo 1 will compare divarasib with sotorasib or adagrasib. SAFFRON will test osimertinib + savolitinib after progression. Can these strategies improve resistance management and reshape treatment sequencing?
- Dr Timos Papagatsias@_timos_
2/6 馃К ADC Competition HORIZON-Breast06, CLARITY-Gastric 01 and TroFuse-005 will test HER2-, CLDN18.2- and TROP2-directed strategies. Efficacy, safety and patient selection could determine competitive positioning.
Source: Dr Timos Papagatsias 路 x.com